Analystreport

Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its price target raised by analysts at HC Wainwright from $3.00 to $4.00. They now have a "buy" rating on the stock.

Cellectar Biosciences, Inc.  (CLRB) 
Last cellectar biosciences, inc. earnings: 11/12 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.cellectar.com